Mobile App

Google Play Apple Store
Relapsed/Refractory Multiple Myeloma Podcast Series: Clinical Viewpoints to Individualize Bispecific Antibody Therapy
AMA/ABS/ANCC - Podcast Series
Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.
Review the activity and claim AMA, ABS, or ANCC credit/contact hour after completion of a brief pretest and posttest/evaluation.






 
Joseph Mikhael, MD, MEd, FRCPC, FACP Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University

Caitlin Costello, MD Caitlin Costello, MD
Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego

20
Supported by an independent educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Launch Date: October 1, 2024
Release Date: October 1, 2024
Expiration Date: September 30, 2025

Mini Module
7806
R_RMultipleMyleloma_Podcast(1730x162).png
True
Hematology

CookieConsent

Change Settings